Phytochemicals in ethyl acetate fraction of Selaginella doederleinii Hieron extract as anti-breast cancer agents: Bioinformatics approach
AIP Conference Proceedings, ISSN: 1551-7616, Vol: 2913, Issue: 1
2023
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures1
- Readers1
Conference Paper Description
Breast cancer ranked first for the most commonly diagnosed cancer worldwide. Inhibiting the mTOR/c-Myc pathway using natural compounds has become an attractive strategy to combat breast cancer. Selaginella doederleinii Hieron, a plant that has long been used to treat various diseases traditionally, offers the opportunity to explore its specific anti-breast cancer potency. This study aimed to identify the phytochemicals in the ethyl acetate fraction of Selaginella doederleinii Hieron extract, to predict their potential as oral medicine, and to analyze their chemical interactions as mTOR/c-Myc inhibitors using molecular docking. The result revealed that the fraction contained 12 phytochemicals, classified into several groups. Three compounds were predicted to possess good oral bioavailability, namely 2-trans,6-trans-Farnesal, Affinisine, and Valeroidine. Meanwhile, Frutinone A, 5-hydroxy-ferulic acid methyl ester, Affinisine, and Valeroidine fulfill all requirements of drug-likeness rules. Syringic acid and 5-hydroxy-ferulic acid methyl ester have good pharmacokinetic properties. Molecular docking analysis showed that Frutinone A had the smallest binding affinity score. Additionally, the six compounds mentioned previously bound several amino acid residues in the Rapamycin-binding site and 10074-G5-binding site, respectively. The similar interactions patterns indicated that the compounds were predicted to inhibit mTOR/c-Myc. The binding affinity values of the compounds are still comparable for inhibitory effects.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know